NCT01381510View on ClinicalTrials.gov

Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database

CompletedOBSERVATIONAL
Enrollment

54,459

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Prostatic Hyperplasia
Interventions
DRUG

5-alpha Reductase Inhibitor (5ARI)

A 5ARI: Either dutasteride or finisteride

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01381510 - Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database | Biotech Hunter | Biotech Hunter